Truist Lifts Immunovant (IMVT) PT to $22 on Updated 2026 Financial Modeling

On January 6, Wolfe Research upgraded Immunovant from Peer Perform to Outperform with a $50 terms people and noted a displacement successful marketplace sentiment regarding Graves’ disease. While the steadfast antecedently expected a valuation re-rating to instrumentality years, Argenx’s introduction into the Graves’ marketplace established a higher valuation level by expanding capitalist appreciation for the space. Wolfe Research highlighted the shrinking abbreviated interval arsenic a motion of increasing marketplace confidence.

Guggenheim expert Yatin Suneja maintained a Buy standing connected Immunovant Inc. (NASDAQ:IMVT) earlier connected December 18 but lowered the terms people to $41 from $44. This accommodation followed the company’s then-recent $550 cardinal equity offering, which the steadfast noted volition pb to a higher stock number and immoderate banal dilution. However, Guggenheim pointed retired that this is balanced by a strengthened equilibrium expanse and an extended currency runway, supporting the company’s continued development.

Immunovant Inc. (NASDAQ:IMVT) is simply a clinical-stage immunology company, develops monoclonal antibodies for the attraction of autoimmune diseases.

While we admit the imaginable of IMVT arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you’re looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double successful 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This nonfiction is primitively published at Insider Monkey.